Abstract：Objective To investigate the efficacy of Gemcitabine combined with Tegafur Gimeracil Oteracil Potassium in the treatment of Anthracycline resistant advanced breast cancer.Methods A total of 60 patients with Anthracycline resistant advanced breast cancer admitted in our hospital from August 2015 to August 2017 were selected as subjects.According to different treatment methods, they were divided into control group (30 cases) and observation group (30 cases).The control group was treated with Gemcitabine Injection.The observation group was treated with Gemcitabine combined with Tegafur Gimeracil Oteracil Potassium.The total effective rate, toxic side effect rate, Kamofsky performance status (KPS) score and numerical raing scale (NRS) score before and after treatment were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group, the significance of calculation was significant (P＜0.05).The incidence of side effects Ⅰlevel in the observation group was 33.3%, the incidence of toxic side effects Ⅱlevel was 40.0%, which were higher than those of the control group(10.0% and 16.3%), the incidence of toxic side effects Ⅲlevel was lower than that in the control group, the differences were statistically significant (P＜0.05).There was no significant difference in KPS score and NRS score between the two groups before treatment (P＞0.05), but the KPS score in the observation group was significantly higher than that in the control group, and the NRS score in the observation group was significantly lower than that in the control group (P＜0.05).Conclusion Anthracycline resistant advanced breast cancer patients using Gemcitabine combined with Tegafur Gimeracil Oteracil Potassium treatment regimen, the clinical effect is good, the toxic side effects are small, can improve physical conditions, alleviate the pain, it is worth in-depth research, and on this basis to promote the application.
京公网安备 11010502046607号